JAK inhibitors in crohn's disease: ready to go?
Fiche publication
Date publication
février 2022
Journal
Expert opinion on investigational drugs
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Dell'Avalle C, D'Amico F, Gabbiadini R, Dal Buono A, Pugliese N, Zilli A, Furfaro F, Fiorino G, Allocca M, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
Crohn's disease (CD) is a chronic, relapsing inflammatory bowel disease that can lead to significant organ damage and impaired quality of life. To date, a considerable proportion of patients does not respond to biologic compounds. It is, therefore, necessary to find alternative options with adequate efficacy and safety profiles in order to increase the chances of obtaining an enduring remission of disease. Janus kinase (JAK) inhibitors are a new class of compounds that might well serve this purpose. The aim of our review is to report the available data from clinical trials testing these new drugs in patients suffering from CD.
Mots clés
Crohn’s disease, IBD, JAK inhibitors, inflammatory bowel disease, small molecules
Référence
Expert Opin Investig Drugs. 2022 Feb 14;:1-17